Abstracts

Adjuvant therapy (AT) in patients (pts) with radically resected ampullary adenocarcinoma (AA): A monocentric retrospective analysis

Background Ampullary adenocarcinoma (AA) is a rare tumor. Radical surgery is the only curative treatment for localized AA. The role of AT is not clearly defined and prev...

06/27/2022

Local recurrence after endoscopic submucosal dissection of early gastric cancer

Background Endoscopic submucosal dissection (ESD) is considered the treatment of choice for early gastric cancer (EGC) with a negligible risk of lymph node metastasis. H...

06/27/2022

MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress

Background Tucatinib (TUC), a highly selective HER2-directed tyrosine kinase inhibitor (TKI) approved in multiple regions for HER2+ metastatic breast cancer, is being de...

Josep Tabernero , MD, PhD;

06/27/2022

Identification of peptides inhibitor clade A member 1 as a novel serum biomarker for gastric cancer and promotes liver metastasis

Background Approximately 9. 9%～18. 7% of gastric cancer (GC) patients experience liver metastasis (LM) during the course of the disease and is highly associated with poo...

06/27/2022

Impact of an educational activity on the competence of oncologists and gastroenterologists regarding the application of molecular-guided therapies for the treatment of advanced cholangiocarcinoma

Background Cholangiocarcinoma (CCA) is a rare, aggressive cancer of the biliary tract with patients often having a poor prognosis and complex genetic heterogeneity. Foll...

06/27/2022

Comprehensive recurrence risk assessment after colectomy, for stage II and III colorectal cancer patients, using genetic profiling, microbiome, and circulating tumor markers

Background Colorectal cancer (CRC) incidence increases in the western population and is considered of a major public health issue. To date, patients’ prognosis is mainly...

06/27/2022

Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric04): A randomized phase 3 study

Background T-DXd is an antibody–drug conjugate consisting of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a topoisomerase I inhibitor. T-DXd is appr...

06/27/2022

Primary gastrointestinal lymphoma in Latin American patients. A 10-year follow-up

Background Gastrointestinal lymphomas constitute 10-15% of non-Hodgkin´s Lymphomas and 30-40% of extra-nodal lymphomas. Primary gastric lymphoma (PGL) is the most common...

06/27/2022

Trial in progress: Neoadjuvant combination therapy of lenvatinib plus transcatheter arterial chemoembolization (TACE) for transplant-eligible patients with large hepatocellular carcinoma

Background Hepatocellular carcinoma HCC is the third leading cause of cancer death worldwide with more than 230,000 cases of HCC since 2000 and an estimated 42,000 new c...

A. Esmail ;

A. Saharia ;

Susheel K. Kodali , MD;

D. Victor ;

K. Heyne ;

R. Ghobrial ;

M. Abdelrahim ;

06/27/2022

Atezolizumab and bevacizumab pre-liver transplantation for patients with hepatocellular carcinoma beyond Milan criteria

Background Hepatocellular carcinoma (HCC) represents the second most common cause of cancer-related death and accounts for over 80% of primary liver cancers worldwide. C...

M. Abdelrahim ;

A. Esmail ;

A. Saharia ;

Susheel K. Kodali , MD;

D. Victor ;

G. OKane ;

06/27/2022